20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 51 employees. Its market capitalization is roughly $365 million. In the fiscal year ended 2025-12-31, CTNM reported $0M in revenue and ($60M) in net income.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $50M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $50M | $0M | — |
| Gross Margin % | — | — | — | 100.0% | — | — |
| Operating Income (EBIT) | ($66M) | ($68M) | ($51M) | ($16M) | ($23M) | ($29M) |
| Operating Margin % | — | — | — | -32.1% | — | — |
| Net Income | ($58M) | ($60M) | ($42M) | $23M | ($24M) | ($29M) |
| Net Margin % | — | — | — | 45.4% | — | — |
| EBITDA | ($66M) | ($68M) | ($42M) | $24M | ($24M) | ($28M) |
| Earnings Per Share (EPS) | $-1.74 | $-2.17 | $-1.63 | $0.90 | $-0.97 | $-1.15 |
| Shares Outstanding (M) | 37M | 28M | 26M | 25M | 25M | 25M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | $0M | $0M | — | $0M | — |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($17M) | ($17M) | ($17M) | ($15M) | ($18M) | ($18M) | $85M | ($13M) |
| Operating Margin % | — | — | — | — | — | — | 35016.9% | — |
| Net Income | ($15M) | ($14M) | ($15M) | ($13M) | ($16M) | ($16M) | ($15M) | ($10M) |
| Net Margin % | — | — | — | — | — | — | -6018.6% | — |
| EBITDA | ($17M) | ($17M) | ($17M) | ($15M) | ($18M) | ($18M) | ($14M) | ($10M) |
| Earnings Per Share (EPS) | $-0.40 | $-0.39 | $-0.49 | $-0.45 | $-0.62 | $-0.62 | $-0.56 | $-0.40 |
| Shares Outstanding (M) | 37M | 37M | 31M | 28M | 26M | 26M | 26M | 26M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($53M) | ($55M) | ($33M) | $19M | ($20M) | ($26M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($53M) | ($56M) | ($33M) | $19M | ($20M) | ($26M) |
| FCF Margin % | — | — | — | 37.9% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($12M) | ($16M) | ($13M) | ($12M) | ($16M) | ($14M) | ($10M) | ($6M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($12M) | ($17M) | ($13M) | ($12M) | ($16M) | ($14M) | ($10M) | ($6M) |
| FCF Margin % | — | — | — | — | — | — | -4284.3% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Assets | $250M | $277M | $213M | $130M | $51M | $71M |
| Cash & Cash Equivalents | $15M | $76M | $22M | $16M | $6M | $5M |
| Total Liabilities | $11M | $16M | $15M | $198M | $11M | $9M |
| Total Debt (Short + Long-Term) | $2M | $2M | $1M | $0M | $5M | $5M |
| Total Shareholders' Equity | $240M | $261M | $198M | ($68M) | $39M | $62M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CTNM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms